Approved for use by diabetics to control blood sugar, liraglutide has also evidenced an ability to slow cognitive decline in a Phase 2b clinical trial, and reduce shrinkage of those areas of the brain ...

Ascendis positioned to drive rapid revenue growthCOPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) ...

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...

While he reduced his Nvidia position, he increased his bets on Novo Nordisk and Eli Lilly ... their trading details with the public on a Form 13F filing. One billionaire investor whom investors ...

On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with the drugmaker Novo Nordisk to develop ... on their patent application as co-inventors, nor ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

Novo Nordisk has ... is directed at the application of artificial intelligence and transcriptomic data from humans to the hunt for new medicines for MASH, a form of non-alcoholic steatohepatitis ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...

It's not just celebrities and TikTok creators jumping on the weight loss drug hype - more than 500,000 people in the UK are ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

The pump-based platform will be a hybrid closed-loop device that will combine an insulin pump, CGM and a dedicated handheld controller or smartphone application ... like Novo Nordisk and Sanofi ...